The discovery and development of Innovative cancer treatments is the group’s primary focus for pharmaceutical research. Year in, year out, onco-hematology attracts no less than 50% of our R&D spendings. We are therefore the second French pharmaceutical company in terms of anti-cancer research.
Our neuropsychiatry research is based on new therapeutic solutions for the treatment of schizophrenia, bipolar disorders, neurodegenerative diseases, depressive disorders, and chronic pain.
Dermatology is a meeting point between our pharmaceutical and dermo-cosmetical R&D teams. It is the cornerstone that captures our desire to be present from “health to beauty”. On the pharmaceutical front, our efforts today focus mainly on infantile hemangioma and onco-dermatological diseases.